QIAsure Methylation Test a breakthrough solution in Women s Health

Transcription

1 QIAsure Página 1 de 12 Home Womens Health QIAsure Methylation Test a breakthrough solution in Women s Health Cervical cancer is the second most common cancer among women aged 15 to 44, affecting more than 500,000 women a year.1 Fortunately, it is almost 100% preventable through advanced screening and early detection of precancer before the disease becomes a danger to a patient s life or reproductive health.

2 Página 2 de 12 QIAsure, the new Women s Health solution from QIAGEN, is a cervical cancer screening test that lets clinicians see what s happening at a molecular level to determine whether cervical cells are actively transforming into cancer. This innovative test objectively detects the presence of biomarkers associated with cervical precancer and cancer in the PCR lab, using the same sample from an HPV or liquid-based cytology test. Whether the result is positive or negative, QIAsure can provide peace of mind for patients so they can live their lives safe, confident, and sure of their reproductive health. QIAsure Brochures Download a brochure for more information

3 Página 3 de 12

4 Página 4 de 12

5 QIAsure Página 5 de 12

6 Página 6 de 12 Making cervical cancer screening more effective and objective Today, women have an 80% chance in their lifetimes of contracting high-risk HPV, the causal agent of cervical cancer. However, only 1 in 10 women with high-risk HPV will develop long-lasting infections that put them at risk for 2 development of cervical cancer. There is growing need for an accurate molecular test to see beyond HPV and determine whether a patient has a high short-term risk of cervical cancer. QIAsure delivers objective assurance that women are safe from cervical cancer following a positive high-risk HPV result or an abnormal cytology result. QIAsure could: Separate out patients with high-risk HPV infections that are transforming into cervical cancer from patients who have low short-term risk of developing cancer Guide surveillance and treatment decisions Prevent women with non-transforming infections from receiving unnecessary treatments Accurate molecular testing from a simple sample

7 Página 7 de 12 QIAsure has been developed for ease of use in primary screening scenarios, following a positive high-risk HPV result or an abnormal cytology result. QIAsure can be performed on the same sample used for primary screening (HPV and/or liquid-based cytology), as well as vaginal selfsamples collected by patients. How QIAsure works QIAsure is a quantitative methylation specific (qmsp) test that looks for specific molecular biomarkers in cervical specimens to objectively detect the presence of biomarkers associated with cervical carcinoma and advanced transforming cervical intraepithelial neoplasia (CIN). The presence of these biomarkers (specifically hypermethylation of host cell genes FAM19A4 and mir124-2) indicates a carcinogenic cell transformation and a high short-term risk of developing cervical cancer. Absence of these biomarkers indicates a low short-term risk of developing cervical cancer. This test can be performed in the PCR lab through industry-standard methods of sample prep/extraction and automation platforms for analysis (clinically validated for Rotor-Gene Q MDx instrument). 3 8

8 Página 8 de 12

9 Página 9 de 12

10 Página 10 de 12

11 Página 11 de 12 #QIAsure Geraldine "Every two minutes a woman dies from cervical cancer. QIAGEN's HC2 Test and # QIAsure Methylation Test can help make a difference." # EUROGIN 17 Jun Geraldine "The # QIAsure Methylation Test differentiates clinically relevant disease from transient infections" - Prof. Chris Meijer # EUROGIN 17 Jun Geraldine "With # QIAsure there's the potential to select women for urgent treatment and Embed View on Twitter

12 Página 12 de 12